Wolfgang Jost discusses the latest treatment and diagnosis approaches in cervical dystonia.
FILMED AT THE INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS (IPMDS), JUNE 2016
WHAT RECENT ADVANCES HAVE BEEN MADE IN THE USE OF BOTULINUM TOXIN IN THE TREATMENT OF CERVICAL DYSTONIA?
00:10 – I think there are two important things. One is the use of ultrasound, so we need meanwhile ultrasound in every patient. And the second thing is a new classification, the so called COL-CAP concept.
WHAT ARE THE MAJOR UNMET NEEDS IN THE TREATMENT OF CERVICAL DYSTONIA?
00:30 – We have to differentiate between the agonist, the antagonist and the compensatory muscle. That’s very useful to treat the patients. The second thing is we need a new score because the TWISTER is not compatible with the COL-CAP concept.
WHAT ARE THE CHALLENGES OF THE DIFFERENTIAL DIAGNOSIS OF CERVICAL DYSTONIA?
00:53 – The challenge is to differentiate between normal cervical dystonia and more complex forms. And I think at the moment we are not able to differentiate with our tools both forms.
WHAT NEW TREATMENT AND DIFFERENTIATION APPROACHES ARE BEING PRESENTED TODAY?
01:11 – Today we demonstrate a new concept with C2 as a fixed point with the differentiation of caput and collum, so you can turn the head or you can turn the neck. And the second important thing is the use of ultrasound to look for especially deeper muscles.
Share this Video
Related Videos In Movement Disorders
EAN 2020 – Time for Action. Predict. Prevent. Repair.
EAN President, Prof. Claudio Bassetti invites you to participate in the EAN 2020 congress. You can register for the virtual congress free-of-charge here. It’s a fantastic opportunity for everyone in the neurology community to benefit from the possibility of education, scientific news and best practice exchange from the comfort of home. Be sure to visit our EAN […]
Angela Vincent, MDS 2019 – Autoimmune movement disorders
It was an absolute pleasure to meet with Angela Vincent, Emeritus Professor of Neuroimmunology at the University of Oxford. Until 2016 she led the clinical and research laboratory at Oxford specialising in antibody-mediated neurological diseases. Despite not being a neurologist herself, she spoke from long experience of helping to identify and characterise pathogenic antibodies in […]
Hélio AG Teive, MDS 2019 – Spinocerebellar ataxia
MDS Congress Scientific Program Committee member, Hélio AG Teive (Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil) kindly talked to us about spinocerebellar ataxia and its geographical diversity. Questions 1. How does spinocerebellar ataxia differ from other ataxias? (0:05) 2. In what regions is spinocerebellar ataxia found? (0:26) 3. What is the reason for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!